{
    "root": "112ae40c-b612-405b-8f68-6d4bf09f9440",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin calcium",
    "value": "20250203",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CALCIUM CARBONATE",
            "code": "H0G9379FGK"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "ATORVASTATIN",
            "code": "A0JWA85V8F"
        }
    ],
    "indications": "atorvastatin calcium tablets indicated : reduce risk : myocardial infarction ( myocardial infarction ) , stroke , revascularization procedures , angina adults multiple risk factors coronary heart disease ( chd ) without clinically evident chd myocardial infarction stroke adults type 2 diabetes mellitus multiple risk factors chd without clinically evident chd non-fatal myocardial infarction , fatal non-fatal stroke , revascularization procedures , hospitalization congestive heart failure , angina adults clinically evident chd adjunct diet reduce low-density lipoprotein cholesterol ( ldl-c ) : adults primary hyperlipidemia . adults pediatric patients aged 10 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct ldl-c-lowering therapies , alone treatments unavailable , reduce ldl-c adults pediatric patients aged 10 years older homozygous familial hypercholesterolemia ( hofh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia hypertriglyceridemia",
    "contraindications": "take orally daily without food ( 2.1 ) . assess ldl-c clinically appropriate , early 4 weeks initiating atorvastatin calcium tablets , adjust necessary ( 2.1 ) . adults ( 2.2 ) : recommended starting 10 20 mg daily ; range 10 mg 80 mg daily . patients requiring ldl-c reduction > 45 % may start 40 mg daily . pediatric patients aged 10 years age older hefh : recommended starting 10 mg daily ; range 10 20 mg daily ( 2.3 ) . pediatric patients aged 10 years age older hofh : recommended starting 10 20 mg daily ; range 10 80 mg daily ( 2.4 ) . full prescribing information atorvastatin calcium tablets modifications due ( 2.5 ) .",
    "warningsAndPrecautions": "80 mg atorvastatin - white off-white , film-coated , oval shaped tablets `` ato `` debossed one side `` 80 `` side . ndc 71335-9646-1 : 30 tablets bottle ndc 71335-9646-2 : 60 tablets bottle ndc 71335-9646-3 : 90 tablets bottle ndc 71335-9646-4 : 180 tablets bottle storage store controlled room temperature 20\u00b0c - 25\u00b0c ( 68\u00b0f - 77\u00b0f ) repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "acute liver failure decompensated cirrhosis [ ( 5.3 ) ] hypersensitivity atorvastatin excipients atorvastatin calcium tablets . hypersensitivity , including anaphylaxis , angioneurotic edema , erythema multiforme , stevens-johnson syndrome , toxic epidermal necrolysis , reported [ ( 6.2 ) ] .",
    "indications_original": "Atorvastatin calcium tablets is indicated:\n                  \n                     To reduce the risk of:\n  \n   \n                           Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                           MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                           Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                        \n                     \n                     As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n  \n   \n                           Adults with primary hyperlipidemia.\n                           Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n  \n   \n                           Primary dysbetalipoproteinemia\n                           Hypertriglyceridemia",
    "contraindications_original": "Take orally once daily with or without food ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). Adults ( 2.2 ): Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. Patients requiring LDL-C reduction >45% may start at 40 mg once daily. Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). See full prescribing information for Atorvastatin calcium tablets dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions_original": "80 mg of atorvastatin - white to off-white, film-coated, oval shaped tablets \"ATO\" debossed on one side and \"80\" on other side.\n                  \n                     NDC 71335-9646-1: 30 Tablets in a BOTTLE\n                     NDC 71335-9646-2: 60 Tablets in a BOTTLE\n                     NDC 71335-9646-3: 90 Tablets in a BOTTLE\n                     NDC 71335-9646-4: 180 Tablets in a BOTTLE\n                  \n                  Storage\n                  Store at controlled room temperature 20\u00b0C - 25\u00b0C (68\u00b0F - 77\u00b0F)\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Acute liver failure or decompensated cirrhosis\n  \n   [see Warnings and Precautions (\n   \n    5.3)]\n  \n   \n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n  \n   [see Adverse Reactions (\n   \n    6.2)]."
}